Thoratec Corp (THOR) 57.58 $THOR
St. Jude in Thoratec buy talks
at Investor's Business Daily - Tue Jul 21, 5:45PM CDT
St. Jude Medical (STJ) is negotiating to buy Thoratec (THOR), a heart device maker, Bloomberg reported, citing people familiar with the situation. Thoratec shares surged 18% to 57.58, hitting an all-time high on the news. St. Jude shares rose 0.2% to...
STJ: 76.71 (+0.14), THOR: 57.58 (+8.77)
Thoratec Has Returned 91.9% Since SmarTrend Recommendation (THOR)
Comtex SmarTrend(R) - Tue Jul 21, 4:49PM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 8 months, Thoratec has returned 91.93% as of today's recent price of $57.58.
THOR: 57.58 (+8.77)
Look for Shares of Thoratec to Potentially Pullback after Yesterday's 17.97% Rise
Comtex SmarTrend(R) - Tue Jul 21, 3:52PM CDT
Thoratec (NASDAQ:THOR) traded in a range yesterday that spanned from a low of $50.00 to a high of $62.05. Yesterday, the shares gained 18.0%, which took the trading range above the 3-day high of $49.68 on volume of 10.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
THOR: 57.58 (+8.77)
Thoratec Rises 17.97% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 21, 3:51PM CDT
Thoratec (NASDAQ:THOR) traded in a range yesterday that spanned from a low of $50.00 to a high of $62.05. Yesterday, the shares gained 18.0%, which took the trading range above the 3-day high of $49.68 on volume of 10.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
THOR: 57.58 (+8.77)
Market Wrap: IBM and United Tech a Real Drag
at The Street - Tue Jul 21, 3:44PM CDT
IBM and UTX accounted for two-thirds of the Dow's 1% drop, and Apple and Microsoft fall after-hours..
KO: 41.19 (-0.19), ABT: 49.76 (-0.30), IBM: 163.07 (-10.15), UTX: 102.71 (-7.77), CMG: 673.07 (-4.93), STJ: 76.71 (+0.14), ILMN: 237.54 (-2.48), THOR: 57.58 (+8.77), EMC: 24.93 (-0.05), BA: 145.00 (-1.72), MSFT: 47.28 (+0.36), AAPL: 130.75 (-1.32), LOCK: 8.15 (-7.91), LXK: 37.75 (-9.57)
Thoratec's HeartMate PHP Product Gets CE Mark Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 1:10PM CDT
Thoratec Corp. (THOR) recently announced that its HeartMate PHP (Percutaneous Heart Pump) product has received the CE Mark approval.
RTIX: 6.71 (+0.29), LDRH: 45.37 (+0.09), THOR: 57.58 (+8.77), SURG: 4.58 (-0.02)
Thoratec Shares Up 54.3% Since SmarTrend's Buy Recommendation (THOR)
Comtex SmarTrend(R) - Tue Jul 14, 11:21AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 8 months, Thoratec has returned 54.25% as of today's recent price of $46.28.
THOR: 57.58 (+8.77)
Thoratec Receives CE Mark Approval For HeartMate PHP(TM)
PR Newswire - Mon Jul 13, 7:45AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced that HeartMate PHP (Percutaneous Heart Pump) received CE Mark approval, permitting sale in the European Union and other international countries. Approval was based on data from the first 30 patients enrolled in the HeartMate PHP SHIELD I CE Mark Trial examining use of PHP to support patients undergoing a high-risk PCI (percutaneous coronary intervention) procedure. Data from all 50 patients enrolled in this study will be presented later in 2015.
THOR: 57.58 (+8.77)
Thoratec's HeartMate III Sees First Implant for CE Mark Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 07, 1:35PM CDT
Thoratec (THOR) recently announced that the first HeartMate III implant has been conducted via mini-thoracotomy.
INCR: 41.80 (-2.07), AHS: 30.91 (-0.19), THOR: 57.58 (+8.77), CGIX: 11.45 (-0.56)
Thoratec Up 48.6% Since SmarTrend Uptrend Call (THOR)
Comtex SmarTrend(R) - Tue Jul 07, 9:45AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 8 months, Thoratec has returned 48.63% as of today's recent price of $44.59.
THOR: 57.58 (+8.77)
Thoratec Announces First HeartMate 3(TM) Implant in European Less Invasive Surgical Trial
PR Newswire - Mon Jul 06, 3:25PM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced the first ever HeartMate 3(TM) implant performed via mini-thoracotomy. This implant begins a European study to evaluate outcomes and complications using less invasive surgical placement through hemi-sternotomy and left thoracotomy techniques. The study will include ten cases performed at three European centers following one initial case to build experience at each center, and will measure the outcomes specified in the HeartMate 3 CE Mark trial after 30 days of follow-up.
THOR: 57.58 (+8.77)
Thoratec Up 50.1% Since SmarTrend Uptrend Call (THOR)
Comtex SmarTrend(R) - Tue Jun 30, 9:22AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 8 months, Thoratec has returned 50.10% as of today's recent price of $45.03.
THOR: 57.58 (+8.77)
Screening The CCC List With The Dividend Spectrum
Nigel Kelly - at Seeking Alpha - Tue Jun 16, 12:39PM CDT
EWBC: 44.65 (+0.04), XOM: 81.66 (-0.10), WSM: 82.50 (-1.06), GWW: 229.94 (-5.16), BNS: 48.82 (-0.20), AOS: 68.37 (-1.00), OZRK: 45.22 (-0.26), VLO: 66.32 (-0.25), MSM: 70.18 (-0.22), CMI: 128.62 (-0.35), NUS: 40.10 (+0.85), QCOM: 65.14 (+1.35), WDR: 45.15 (-0.02), WTBA: 19.68 (-0.51), ACN: 100.39 (-0.33), PII: 153.38 (+0.45), WHG: 60.90 (+0.56), TROW: 79.07 (-0.28), AFSI: 67.00 (-0.20), DIS: 119.31 (-0.27), TJX: 68.53 (-0.57), JKHY: 68.91 (-0.14), RY: 59.19 (-0.13), TXN: 50.23 (+0.14), MGA: 54.26 (-0.16), THOR: 57.58 (+8.77), GPS: 36.93 (-0.68), EL: 89.24 (+0.71)
Shares of THOR Up 49.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jun 15, 11:16AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 7 months, Thoratec has returned 49.70% as of today's recent price of $44.91.
THOR: 57.58 (+8.77)
Thoratec Has Returned 52.0% Since SmarTrend Recommendation (THOR)
Comtex SmarTrend(R) - Mon Jun 08, 9:49AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 7 months, Thoratec has returned 52.03% as of today's recent price of $45.61.
THOR: 57.58 (+8.77)
Uptrend Call Working As Thoratec Stock Rises 51.3% (THOR)
Comtex SmarTrend(R) - Mon Jun 01, 9:20AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 7 months, Thoratec has returned 51.27% as of today's recent price of $45.38.
THOR: 57.58 (+8.77)
FDA Conditional Approval for Thoratec's HeartMate PHP Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 27, 1:30PM CDT
Thoratec (THOR) recently announced that it has received a conditional approval from the FDA for a U.S. IDE clinical trial to investigate the use of its HeartMate PHP product in the treatment of heart diseases.
INCR: 41.80 (-2.07), AHS: 30.91 (-0.19), THOR: 57.58 (+8.77), CGIX: 11.45 (-0.56)
Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast
PR Newswire - Tue May 26, 3:25PM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, said today it will participate in the Goldman Sachs 36th Annual Healthcare Conference on Tuesday, June 9.
THOR: 57.58 (+8.77)
Thoratec Receives Conditional FDA Approval For The Shield II U.S. Clinical Trial For HeartMate PHP
PR Newswire - Tue May 26, 8:00AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced that the FDA has granted conditional approval for a U.S. IDE clinical trial to investigate use of the HeartMate PHP acute catheter-based heart pump in patients undergoing a high-risk percutaneous coronary intervention. The SHIELD II (Supporting patients undergoing HIgh-risk PCI using a high-flow pErcutaneous Left ventricular support Device) U.S. clinical trial will randomize up to 425 patients at up to 60 sites against the Impella® 2.5 at a 2:1 ratio. Individual sites may immediately begin randomization after performing a series of up to three HeartMate PHP procedures for purposes of training and familiarity. The primary endpoint will measure non-inferiority based on a composite of adverse events at 90 days of follow-up. Final FDA approval is expected in the coming months pending resolution of certain routine technical questions.
THOR: 57.58 (+8.77)
St. Jude in Thoratec buy talks
at Investor's Business Daily - Tue Jul 21, 5:45PM CDT
St. Jude Medical (STJ) is negotiating to buy Thoratec (THOR), a heart device maker, Bloomberg reported, citing people familiar with the situation. Thoratec shares surged 18% to 57.58, hitting an all-time high on the news. St. Jude shares rose 0.2% to...
STJ: 76.71 (+0.14), THOR: 57.58 (+8.77)
Thoratec Has Returned 91.9% Since SmarTrend Recommendation (THOR)
Comtex SmarTrend(R) - Tue Jul 21, 4:49PM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 8 months, Thoratec has returned 91.93% as of today's recent price of $57.58.
THOR: 57.58 (+8.77)
Look for Shares of Thoratec to Potentially Pullback after Yesterday's 17.97% Rise
Comtex SmarTrend(R) - Tue Jul 21, 3:52PM CDT
Thoratec (NASDAQ:THOR) traded in a range yesterday that spanned from a low of $50.00 to a high of $62.05. Yesterday, the shares gained 18.0%, which took the trading range above the 3-day high of $49.68 on volume of 10.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
THOR: 57.58 (+8.77)
Thoratec Rises 17.97% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 21, 3:51PM CDT
Thoratec (NASDAQ:THOR) traded in a range yesterday that spanned from a low of $50.00 to a high of $62.05. Yesterday, the shares gained 18.0%, which took the trading range above the 3-day high of $49.68 on volume of 10.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
THOR: 57.58 (+8.77)
Market Wrap: IBM and United Tech a Real Drag
at The Street - Tue Jul 21, 3:44PM CDT
IBM and UTX accounted for two-thirds of the Dow's 1% drop, and Apple and Microsoft fall after-hours..
KO: 41.19 (-0.19), ABT: 49.76 (-0.30), IBM: 163.07 (-10.15), UTX: 102.71 (-7.77), CMG: 673.07 (-4.93), STJ: 76.71 (+0.14), ILMN: 237.54 (-2.48), THOR: 57.58 (+8.77), EMC: 24.93 (-0.05), BA: 145.00 (-1.72), MSFT: 47.28 (+0.36), AAPL: 130.75 (-1.32), LOCK: 8.15 (-7.91), LXK: 37.75 (-9.57)
Thoratec's HeartMate PHP Product Gets CE Mark Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 1:10PM CDT
Thoratec Corp. (THOR) recently announced that its HeartMate PHP (Percutaneous Heart Pump) product has received the CE Mark approval.
RTIX: 6.71 (+0.29), LDRH: 45.37 (+0.09), THOR: 57.58 (+8.77), SURG: 4.58 (-0.02)
Thoratec Shares Up 54.3% Since SmarTrend's Buy Recommendation (THOR)
Comtex SmarTrend(R) - Tue Jul 14, 11:21AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 8 months, Thoratec has returned 54.25% as of today's recent price of $46.28.
THOR: 57.58 (+8.77)
Thoratec Receives CE Mark Approval For HeartMate PHP(TM)
PR Newswire - Mon Jul 13, 7:45AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced that HeartMate PHP (Percutaneous Heart Pump) received CE Mark approval, permitting sale in the European Union and other international countries. Approval was based on data from the first 30 patients enrolled in the HeartMate PHP SHIELD I CE Mark Trial examining use of PHP to support patients undergoing a high-risk PCI (percutaneous coronary intervention) procedure. Data from all 50 patients enrolled in this study will be presented later in 2015.
THOR: 57.58 (+8.77)
Thoratec's HeartMate III Sees First Implant for CE Mark Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 07, 1:35PM CDT
Thoratec (THOR) recently announced that the first HeartMate III implant has been conducted via mini-thoracotomy.
INCR: 41.80 (-2.07), AHS: 30.91 (-0.19), THOR: 57.58 (+8.77), CGIX: 11.45 (-0.56)
Thoratec Up 48.6% Since SmarTrend Uptrend Call (THOR)
Comtex SmarTrend(R) - Tue Jul 07, 9:45AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 8 months, Thoratec has returned 48.63% as of today's recent price of $44.59.
THOR: 57.58 (+8.77)
Thoratec Announces First HeartMate 3(TM) Implant in European Less Invasive Surgical Trial
PR Newswire - Mon Jul 06, 3:25PM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced the first ever HeartMate 3(TM) implant performed via mini-thoracotomy. This implant begins a European study to evaluate outcomes and complications using less invasive surgical placement through hemi-sternotomy and left thoracotomy techniques. The study will include ten cases performed at three European centers following one initial case to build experience at each center, and will measure the outcomes specified in the HeartMate 3 CE Mark trial after 30 days of follow-up.
THOR: 57.58 (+8.77)
Thoratec Up 50.1% Since SmarTrend Uptrend Call (THOR)
Comtex SmarTrend(R) - Tue Jun 30, 9:22AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 8 months, Thoratec has returned 50.10% as of today's recent price of $45.03.
THOR: 57.58 (+8.77)
Screening The CCC List With The Dividend Spectrum
Nigel Kelly - at Seeking Alpha - Tue Jun 16, 12:39PM CDT
EWBC: 44.65 (+0.04), XOM: 81.66 (-0.10), WSM: 82.50 (-1.06), GWW: 229.94 (-5.16), BNS: 48.82 (-0.20), AOS: 68.37 (-1.00), OZRK: 45.22 (-0.26), VLO: 66.32 (-0.25), MSM: 70.18 (-0.22), CMI: 128.62 (-0.35), NUS: 40.10 (+0.85), QCOM: 65.14 (+1.35), WDR: 45.15 (-0.02), WTBA: 19.68 (-0.51), ACN: 100.39 (-0.33), PII: 153.38 (+0.45), WHG: 60.90 (+0.56), TROW: 79.07 (-0.28), AFSI: 67.00 (-0.20), DIS: 119.31 (-0.27), TJX: 68.53 (-0.57), JKHY: 68.91 (-0.14), RY: 59.19 (-0.13), TXN: 50.23 (+0.14), MGA: 54.26 (-0.16), THOR: 57.58 (+8.77), GPS: 36.93 (-0.68), EL: 89.24 (+0.71)
Shares of THOR Up 49.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jun 15, 11:16AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 7 months, Thoratec has returned 49.70% as of today's recent price of $44.91.
THOR: 57.58 (+8.77)
Thoratec Has Returned 52.0% Since SmarTrend Recommendation (THOR)
Comtex SmarTrend(R) - Mon Jun 08, 9:49AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 7 months, Thoratec has returned 52.03% as of today's recent price of $45.61.
THOR: 57.58 (+8.77)
Uptrend Call Working As Thoratec Stock Rises 51.3% (THOR)
Comtex SmarTrend(R) - Mon Jun 01, 9:20AM CDT
SmarTrend identified an Uptrend for Thoratec (NASDAQ:THOR) on November 17th, 2014 at $30.00. In approximately 7 months, Thoratec has returned 51.27% as of today's recent price of $45.38.
THOR: 57.58 (+8.77)
FDA Conditional Approval for Thoratec's HeartMate PHP Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 27, 1:30PM CDT
Thoratec (THOR) recently announced that it has received a conditional approval from the FDA for a U.S. IDE clinical trial to investigate the use of its HeartMate PHP product in the treatment of heart diseases.
INCR: 41.80 (-2.07), AHS: 30.91 (-0.19), THOR: 57.58 (+8.77), CGIX: 11.45 (-0.56)
Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast
PR Newswire - Tue May 26, 3:25PM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, said today it will participate in the Goldman Sachs 36th Annual Healthcare Conference on Tuesday, June 9.
THOR: 57.58 (+8.77)
Thoratec Receives Conditional FDA Approval For The Shield II U.S. Clinical Trial For HeartMate PHP
PR Newswire - Tue May 26, 8:00AM CDT
Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced that the FDA has granted conditional approval for a U.S. IDE clinical trial to investigate use of the HeartMate PHP acute catheter-based heart pump in patients undergoing a high-risk percutaneous coronary intervention. The SHIELD II (Supporting patients undergoing HIgh-risk PCI using a high-flow pErcutaneous Left ventricular support Device) U.S. clinical trial will randomize up to 425 patients at up to 60 sites against the Impella® 2.5 at a 2:1 ratio. Individual sites may immediately begin randomization after performing a series of up to three HeartMate PHP procedures for purposes of training and familiarity. The primary endpoint will measure non-inferiority based on a composite of adverse events at 90 days of follow-up. Final FDA approval is expected in the coming months pending resolution of certain routine technical questions.
THOR: 57.58 (+8.77)
